Prevalence of hypercoagulable disorders in inflammatory bowel disease

References

• Lam A, Borda IT, Inwood MJ, Thomson S. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 1975;68:245–51.
   PubMed Web of Science ®Google Scholar
• Hudson M, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996;38:733–7.
   PubMedGoogle Scholar
• Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001;46:644–8.
   PubMed Web of Science ®Google Scholar
• Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005;3:617–28.
   PubMed Web of Science ®Google Scholar
• Kume K, Yamasaki M, Tashiro M, Yoshikawa I, Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 2007;46:1323–9.
   PubMedGoogle Scholar
• Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005;100:2036–41.
   PubMedGoogle Scholar
• Peppercorn MA. Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults. UpToDate on line 20.3 Wellesley: 2012. http://www.uptodate.com.
   Google Scholar
• Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Tromb Haemost 2001;85:430–4.
   PubMed Web of Science ®Google Scholar
• Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542–8.
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97–101.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:41–5.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272–80.
   PubMed Web of Science ®Google Scholar
• Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010;139:779–87.
   PubMed Web of Science ®Google Scholar
• Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657–63.
   PubMed Web of Science ®Google Scholar
• Issa H, Al-Momen S, Bseiso B, Al-Janobi GA, Aljama MA, Almousa FA, et al. Thromboembolism in inflammatory bowel diseases: a report from Saudi Arabia. Clin Exp Gastroenterol 2011;4:1–7.
   PubMedGoogle Scholar
• Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937–43.
   PubMed Web of Science ®Google Scholar
• Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011;106:713–18.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Peppercorn MA. Overview of the medical management of severe or refractory Crohn's disease in adults. UpToDate on line 20.3 Wellesley: 2012. http://www.uptodate.com.
   Google Scholar
• Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis. Hepatogastroenterology 2007;54:1417–21.
   PubMedGoogle Scholar
• Lee LC, Spittell JA Jr, Sauer WG, Owen CA Jr, Thompson JH Jr. Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors. Gastroenterology 1968;54:76–85.
   PubMed Web of Science ®Google Scholar
• Souto JC, Martínez E, Roca M, Mateo J, Pujol J, González D, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883–9.
   PubMed Web of Science ®Google Scholar
• de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989;30:188–94.
   PubMed Web of Science ®Google Scholar
• Conlan MG, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989;34:1089–93.
   PubMed Web of Science ®Google Scholar
• Vecchi M, Cattaneo M, de Franchis R, Mannucci PM. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 1991;21:165–70.
   PubMedGoogle Scholar
• Stadnicki A, Kloczko J, Nowak A, Sierka E, Sliwiński Z. Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis. Am J Gastroenterol 1991;86:690–3.
   PubMedGoogle Scholar
• Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn's disease. Blood Coagul Fibrinolysis 1992;3:773–8.
   PubMedGoogle Scholar
• Hudson M, Wakefield AJ, Hutton RA, Sankey EA, Dhillon AP, More L, et al. Factor XIIIA subunit and Crohn's disease. Gut 1993;34:75–9.
   PubMed Web of Science ®Google Scholar
• Chamouard P, Grunebaum L, Wiesel ML, Frey PL, Wittersheim C, Sapin R, et al. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995;7:1183–8.
   PubMed Web of Science ®Google Scholar
• Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997;9:1213–17.
   PubMed Web of Science ®Google Scholar
• Chamouard P, Grunebaum L, Wiesel ML, Sibilia J, Coumaros G, Wittersheim C, et al. Significance of diminished factor XIII in Crohn's disease. Am J Gastroenterol 1998;93:610–14.
   PubMedGoogle Scholar
• Magro F, Dinis-Ribeiro M, Araújo FM, Pereira P, Fraga MC, Cunha-Ribeiro LM, et al. High prevalence of combined trombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003;15:1157–63.
   PubMed Web of Science ®Google Scholar
• Yurekli BP, Aksoy DY, Aybar M, Egesel T, Gurgey A, Hascelik G, et al. The search for a common thrombophilic state during the active state of inflammatory bowel disease. J Clin Gastroenterol 2006;40:809–13.
   PubMedGoogle Scholar
• Maher MM, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J Gastroenterol 2008;14:192–7.
   PubMedGoogle Scholar
• Zezos P, Papaioannou G, Nikolaidis N, Patsiaoura K, Vassiliadis T, Mpoumponaris A, et al. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis. Med Sci Monit 2009;15:563–72.
   Web of Science ®Google Scholar
• Shen J, Ran ZH, Zhang Y, Cai Q, Yin HM, Zhou XT, et al. Biomarkers of altered coagulation and fibronolysis as measured of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis. Thromb Res 2009;123:604–11.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Granger DN. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis 2009;15:1245–55.
   PubMed Web of Science ®Google Scholar
• Stadnicki A. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol 2012;10:659–69.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Yilmaz CE, Granger DN. Role of tumor necrosis factor-α in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis 2011;17:2217–23.
   PubMed Web of Science ®Google Scholar
• Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220–5.
   PubMed Web of Science ®Google Scholar
• Rijken DC, Sprengers ED, van der Hoeven RJ, Kluftl C, Engesser L. Plasminogen activator inhibitor 1 (PAI-1) antigen levels in human plasma samples. Fibrinolysis 1988;2:79–82.
   Google Scholar
• Wolf M, Boyer-Neumann C, Martinoli JL, Leroy-Matheron C, Amiral J, Meyer D, et al. A new functional assay for human protein S activity using activated factor V as substrate. Tromb Haemost 1989;62:1144–5.
   PubMed Web of Science ®Google Scholar
• Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:520–1.
   Google Scholar
• Trossaert M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996;75:520–6.
   Google Scholar
• Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101–6.
   PubMed Web of Science ®Google Scholar
• Hoek JA, Sturk A, ten Cate JW, Lamping RJ, Berends F, Borm JJ. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 1988;34:2058–62.
   PubMed Web of Science ®Google Scholar
• Pelzer H, Schwarz A, Stuber W. Determination of human protrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153–9.
   PubMed Web of Science ®Google Scholar
• De Raucourt E, Meyer G, Landais P, Gouaref Z, Morinet P, Monge F, et al. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment. Blood Coagul Fibrinolysis 2000;11:249–53.
   PubMedGoogle Scholar
• Tripodi A, Cattaneo M, Molteni A, Cesana BM, Mannucci PM. Changes of prothrombin fragment 1+2 (F1+2) as a function of increasing intensity of oral anticoagulation - considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment. Thromb Haemost 1998;79:571–3.
   PubMedGoogle Scholar
• Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 1987;69:1600–4.
   PubMed Web of Science ®Google Scholar
• Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985;54:684–7.
   PubMedGoogle Scholar
• Korniger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986;41:527–35.
   PubMedGoogle Scholar
• Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991;66:6–15.
   PubMed Web of Science ®Google Scholar
• Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 1987;46:527–37.
   PubMed Web of Science ®Google Scholar
• Bures J, Horacek J, Pecka M, Tichy M, Cervenka B, Kral B, et al. Thrombocytes as an indicator of activity in Crohn's disease treated with total parenteral and/or enteral nutrition (Article in Czech). Vnitr Lek 1994;40:84–8.
   PubMedGoogle Scholar
• Douda T, Bures J, Rejchrt S, Kopacova M, Pecka M, Maly J. Mean platelet volume in Crohn's disease patients (Article in Czech). Cas Lek Cesk 2006;145:870–3.
   PubMedGoogle Scholar
• Bauer KA. TFPI and venous thrombosis. Blood 2003;101:4228–9.
   Google Scholar
• Leung LLK. Overview of hemostasis. UpToDate on line 20.3 Wellesley: 2012. http://www.uptodate.com.
   Google Scholar
• Morrissey JH. Tissue factor and factor VII initiation of coagulation (p 17). In Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and thrombosis. Basic principles & clinical practice. 4th ed. Philadephia: Lippincott Williams & Wilkins; 2001.
   Google Scholar
• Souto JC, Martínez E, Roca M, Mateo J, Pujol J, González D, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883–9.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661–5.
   PubMed Web of Science ®Google Scholar
• Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982;12:351–9.
   PubMed Web of Science ®Google Scholar
• Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:882–7.
   PubMed Web of Science ®Google Scholar
• Karoui S, Laz S, Serghini M, Bibani N, Boubaker J, Filali A. Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci 2011;56:1801–5.
   PubMedGoogle Scholar
• Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, et al. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol 2009;24:1768–74.
   PubMedGoogle Scholar
• Prantera C, Davoli M, Lorenzetti R, Pallone F, Marcheggiano A, Iannoni C, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988;10:41–5.
   PubMedGoogle Scholar
• Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011;46:1081–91.
   PubMed Web of Science ®Google Scholar
• Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007;52:2063–8.
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707–12.
   PubMed Web of Science ®Google Scholar
• Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis 2011;5:423–9.
   PubMed Web of Science ®Google Scholar
• Bures J, Fixa B, Komarkova O, Fingerland A. Non-smoking: a feature of ulcerative colitis. Br Med J 1982;285:440.
   Google Scholar
• Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007;13:6134–9.
   PubMed Web of Science ®Google Scholar
• Giardina EG. Cardiovascular effects of nicotine. UpToDate on line 20.3 Wellesley: 2012. http://www.uptodate.com.
   Google Scholar
• Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776–81.
   PubMed Web of Science ®Google Scholar
• Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004;99:938–45.
   PubMed Web of Science ®Google Scholar
• Yüksel O, Helvaci K, Başar O, Köklü S, Caner S, Helvaci N, et al. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets 2009;20:277–81.
   PubMed Web of Science ®Google Scholar
• Törüner M, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, et al. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk J Gastroenterol 2004;15:250–2.
   PubMedGoogle Scholar
• Papa A, De Stefano V, Gasbarrini A, Chiusolo P, Cianci R, Casorelli I, et al. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000;11:499–503.
   PubMedGoogle Scholar
• Yilmaz S, Bayan K, Tüzün Y, Batun S, Altintas A. A comprihensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey. J Thromb Thrombolysis 2006;22:205–12.
   PubMedGoogle Scholar
• Attvall E, Frigyesi A, Sternby B. What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int J Colorectal Dis 2006;21:705–10.
   PubMedGoogle Scholar
• Novacek G, Miehsler W, Palkovits J, Reinisch W, Waldhör T, Kapiotis S, et al. Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease. World J Gastroenterol 2006;12:6026–31.
   PubMedGoogle Scholar
• Tsiolakidou G, Koutroubakis IE. Thrombosis and inflammatory bowel disease – the role of genetic risk factors. World J Gastroenterol 2008;14:4440–4.
   PubMedGoogle Scholar
• Bauer KA. Activated protein C resistance and factor V Leiden. Antithrombin (ATIII) deficiency. Protein C deficiency. Protein S deficiency. Prothrombin gene mutation. UpToDate on line 20.3 Wellesley: 2012. http://www.uptodate.com.
   Google Scholar
• Zauber NP, SabbathSolitare M, Rajoria G, Mogan G. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease. J Clin Gastroenterol 1998;27:215–16.
   PubMedGoogle Scholar
• Kvasnicka J, Hajkova J, Bobcikova P, Kvasnicka T, Duskova D, Poletinova S, et al. Prevalence of thrombophilic mutations of FV Leiden, prothrombin G20210A and PAl-1 4G/5G and their combinations in a group of 1450 healthy middle-aged individuals in the Prague and Central Bohemian regions (results of FRET real-time PCR assay) (Article in Czech). Cas Lek Cesk 2012;151:76–82.
   PubMedGoogle Scholar